LIMN Merger with InnocsAI: $0.20/share Closing Payment, 1.6B Shares, Contingent 20% Sale Proceeds Rights, IBC101 CAR-T (CD19/CD22) Korea Phase 1/2a DLBCL Lead Site Seoul St. Mary’s Hospital, Inc101 Dual-Antigen MSLN/CD276 Solid Tumor Preclinical AND-Gate Design
Liminatus Pharma, Inc. Class A Common Stock · Now $0.18
+31% in 1d after detection
Post-detection moves
1h
—
1d
+31%
3d
-13%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS